ARWR
Neutral signalScored 2026-08-22 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Arrowhead Pharmaceuticals, Inc.
- Nom
- Arrowhead Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $8.2B
- Employés
- 711
- PDG
- Christopher R. Anzalone
- Site web
- https://arrowheadpharma.com
- Marché
- ALNYARCTIONSPRQRSLNWVE
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 13 600 titres (~1 186 600,00 $ US)
- Insiders
- OLUKOTUN ADEOYE YPERRY MICHAEL S
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,186,600
Avg sell (VWAP, 90d window) $87.25 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-18 | OLUKOTUN ADEOYE Y | Sell · S | 2,000 | $86.96 | $173,920 | Form 4 |
| 2026-08-18 | PERRY MICHAEL S | Sell · S | 11,600 | $87.30 | $1,012,680 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-01-31 | Daniel Goldman | Sale | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-22 Drivers: fundamentals. Moteurs : fondamentaux.
ARWR presents a compelling inflection story with its first positive EBITDA milestone, strong liquidity (80), and a multi-layered catalyst stack — Q3 2026 earnings beat, positive Phase III plozasiran data in SHTG, and…
The first sentence of the analysis written for ARWR on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 4.86 · operating margin 12%
Market snapshot
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | -423.7% | 94.8% | 95.7% | 100.0% | |
| Ebit Margin | 17.0% | -16336.5% | -78.2% | -71.0% | -101.9% | |
| Ebitda Margin | 19.9% | -15812.8% | -73.0% | -66.7% | -95.9% | |
| Operating Profit Margin | 11.9% | -16927.1% | -85.2% | -73.4% | -107.8% | |
| Pretax Profit Margin | 6.2% | -17247.5% | -85.8% | -71.0% | -101.9% | |
| Continuous Operations Profit Margin | 3.6% | -17169.6% | -86.9% | -72.6% | -101.9% | |
| Net Profit Margin | -0.2% | -16882.4% | -85.3% | -72.4% | -101.9% | |
| Bottom Line Profit Margin | -0.2% | -16882.4% | -85.3% | -72.4% | -101.9% | |
| Current Ratio | 4.863 | 6.741 | 3.978 | 2.919 | 2.625 | |
| Quick Ratio | 4.863 | 6.741 | 3.978 | 3.075 | 2.595 | |
| Solvency Ratio | 0.025 | -0.612 | -0.403 | -0.605 | -0.440 | |
| Cash Ratio | 1.159 | 0.995 | 1.052 | 0.778 | 1.259 | |
| Price To Earnings Ratio | -2,827.049 | -3.874 | -13.995 | -19.790 | -45.904 | |
| Price To Earnings Growth Ratio | 28.340 | -0.024 | -0.935 | -0.868 | -0.742 | |
| Forward Price To Earnings Growth Ratio | 28.340 | -0.024 | -0.935 | -0.868 | -0.742 | |
| Price To Earnings Diluted Ratio | -2,827.049 | -3.874 | -13.995 | -19.790 | -45.904 | |
| Price To Earnings Diluted Growth Ratio | 28.340 | -0.024 | -0.935 | -0.868 | -0.742 | |
| Price To Book Ratio | 9.899 | 12.512 | 10.571 | 8.743 | 15.843 | |
| Price To Sales Ratio | 5.562 | 653.398 | 11.915 | 14.325 | 46.836 | |
| Price To Free Cash Flow Ratio | 29.406 | -3.839 | -8.676 | -18.445 | 43.838 | |
| Price To Operating Cash Flow Ratio | 25.693 | -5.013 | -18.639 | -25.595 | 37.807 | |
| Debt To Assets Ratio | 0.264 | 0.747 | 0.501 | 0.118 | 0.036 | |
| Debt To Equity Ratio | 0.786 | 4.594 | 1.413 | 0.205 | 0.062 | |
| Debt To Capital Ratio | 0.440 | 0.821 | 0.586 | 0.170 | 0.059 | |
| Long Term Debt To Capital Ratio | 0.316 | 0.798 | 0.497 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.972 | 6.146 | 2.821 | 1.736 | 1.737 | |
| Working Capital Turnover Ratio | 1.231 | 0.008 | 0.829 | 0.964 | 0.532 | |
| Operating Cash Flow Ratio | 0.918 | -4.486 | -1.459 | -0.980 | 1.169 | |
| Operating Cash Flow Sales Ratio | 0.216 | -130.344 | -0.639 | -0.560 | 1.239 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | 1.306 | 2.148 | 1.388 | 0.862 | |
| Debt Service Coverage Ratio | 1.109 | -14.440 | -6.177 | -59.825 | -58.925 | |
| Interest Coverage Ratio | 1.101 | -18.579 | -11.186 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 4.489 | -72.982 | -14.569 | -49.039 | 76.139 | |
| Operating Cash Flow Coverage Ratio | 0.490 | -0.543 | -0.401 | -1.669 | 6.706 | |
| Capital Expenditure Coverage Ratio | 7.922 | -3.272 | -0.871 | -2.579 | 7.269 | |
| Dividend Paid And Capex Coverage Ratio | 7.922 | -3.272 | -0.871 | -2.579 | 7.269 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 28.837 | -5.466 | -17.880 | -21.307 | -47.654 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | ▲523.7% | ▲106.6% |
| Ebit Margin | 17.0% | ▲16353.5% | ▲3331.1% |
| Ebitda Margin | 19.9% | ▲15832.7% | ▲3225.6% |
| Operating Profit Margin | 11.9% | ▲16938.9% | ▲3448.2% |
| Pretax Profit Margin | 6.2% | ▲17253.8% | ▲3506.2% |
| Continuous Operations Profit Margin | 3.6% | ▲17173.2% | ▲3489.1% |
| Net Profit Margin | -0.2% | ▲16882.2% | ▲3428.2% |
| Bottom Line Profit Margin | -0.2% | ▲16882.2% | ▲3428.2% |
| Current Ratio | 4.863 | ▼-1.878 | ▲0.638 |
| Quick Ratio | 4.863 | ▼-1.878 | ▲0.613 |
| Solvency Ratio | 0.025 | ▲0.638 | ▲0.432 |
| Cash Ratio | 1.159 | ▲0.164 | ▲0.110 |
| Price To Earnings Ratio | -2827.049 | ▼-2823.175 | ▼-2244.927 |
| Price To Earnings Growth Ratio | 28.340 | ▲28.364 | ▲23.186 |
| Forward Price To Earnings Growth Ratio | 28.340 | ▲28.364 | ▲23.186 |
| Price To Earnings Diluted Ratio | -2827.049 | ▼-2823.175 | ▼-2244.927 |
| Price To Earnings Diluted Growth Ratio | 28.340 | ▲28.364 | ▲23.186 |
| Price To Book Ratio | 9.899 | ▼-2.613 | ▼-1.615 |
| Price To Sales Ratio | 5.562 | ▼-647.836 | ▼-140.845 |
| Price To Free Cash Flow Ratio | 29.405 | ▲33.245 | ▲20.949 |
| Price To Operating Cash Flow Ratio | 25.694 | ▲30.706 | ▲22.843 |
| Debt To Assets Ratio | 0.264 | ▼-0.483 | ▼-0.069 |
| Debt To Equity Ratio | 0.786 | ▼-3.808 | ▼-0.626 |
| Debt To Capital Ratio | 0.440 | ▼-0.381 | ▲0.025 |
| Long Term Debt To Capital Ratio | 0.316 | ▼-0.483 | ▼-0.007 |
| Financial Leverage Ratio | 2.972 | ▼-3.174 | ▼-0.110 |
| Working Capital Turnover Ratio | 1.231 | ▲1.223 | ▲0.518 |
| Operating Cash Flow Ratio | 0.918 | ▲5.405 | ▲1.886 |
| Operating Cash Flow Sales Ratio | 0.216 | ▲130.560 | ▲26.234 |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | ▼-0.432 | ▼-0.442 |
| Debt Service Coverage Ratio | 1.109 | ▲15.549 | ▲28.760 |
| Interest Coverage Ratio | 1.101 | ▲19.680 | ▲6.834 |
| Short Term Operating Cash Flow Coverage Ratio | 4.489 | ▲77.471 | ▲15.681 |
| Operating Cash Flow Coverage Ratio | 0.490 | ▲1.034 | ▼-0.426 |
| Capital Expenditure Coverage Ratio | 7.922 | ▲11.193 | ▲6.228 |
| Dividend Paid And Capex Coverage Ratio | 7.922 | ▲11.193 | ▲6.228 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 28.837 | ▲34.304 | ▲41.531 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.61B | $2.32B | $2.87B | $3.48B | $6.48B | |
| Enterprise value | $4.75B | $3.07B | $3.14B | $3.46B | $6.32B | |
| EV / Sales | 5.73x | 864.39x | 13.05x | 14.22x | 45.69x | |
| EV / Op. cash flow | 26.47x | -6.63x | -20.41x | -25.40x | 36.88x | |
| EV / Free cash flow | 30.30x | -5.08x | -9.50x | -18.30x | 42.76x | |
| EV / EBITDA | 28.84x | -5.47x | -17.88x | -21.31x | -47.65x | |
| Net debt / EBITDA | 0.85x | -1.33x | -1.55x | 0.16x | 1.20x | |
| Current ratio | 4.86x | 6.74x | 3.98x | 2.92x | 2.62x | |
| Income quality | 5.96x | 0.76x | 0.73x | 0.77x | -1.22x | |
| Graham net-net | $0 | -$2 | -$1 | $1 | $1 | |
| Tax burden | -3.2% | 97.9% | 99.4% | 101.9% | 100.0% | |
| Interest burden | 36.6% | 105.6% | 109.7% | 100.0% | 100.0% | |
| Working capital | $755.2M | $592.3M | $314.1M | $266.4M | $238.1M | |
| Invested capital | $1.19B | $1.03B | $659.9M | $447.0M | $317.7M | |
| Return on assets | -0.1% | -52.6% | -26.8% | -25.4% | -19.8% | |
| Operating ROA | 7.8% | -63.1% | -28.1% | -25.5% | -24.2% | |
| Return on tangible assets | -0.1% | -53.0% | -27.2% | -25.9% | -20.2% | |
| Return on equity | -0.3% | -323.3% | -75.7% | -44.2% | -34.5% | |
| Return on invested capital | 4.6% | -57.4% | -30.6% | -32.1% | -26.3% | |
| Return on capital employed | 8.3% | -58.0% | -31.1% | -32.3% | -26.4% | |
| Earnings yield | -0.0% | -25.8% | -7.2% | -5.1% | -2.2% | |
| Free cash flow yield | 3.4% | -26.0% | -11.5% | -5.4% | 2.3% | |
| Capex / Op. cash flow | 12.6% | -30.6% | -114.8% | -38.8% | 13.8% | |
| Capex / Depreciation | 94.7% | 760.8% | 1414.7% | 506.4% | 285.1% | |
| Capex / Sales | 2.7% | 3983.9% | 73.4% | 21.7% | 17.0% | |
| SG&A / Sales | 14.7% | 2726.6% | 37.8% | 51.2% | 58.6% | |
| R&D / Sales | 73.2% | 13776.9% | 142.2% | 118.6% | 149.2% | |
| Stock comp / Sales | 7.6% | 2083.0% | 32.5% | 49.7% | 55.4% | |
| Intangibles / Total assets | 0.5% | 0.8% | 1.3% | 1.7% | 1.9% | |
| Days sales outstanding | 3d | 0d | 0d | 2d | 27d | |
| Days payables outstanding | 0d | 224d | 1048d | 100d | 0d | |
| Operating cycle | 3d | 0d | 0d | -755d | 27d | |
| Cash conversion cycle | 3d | -224d | -1048d | -855d | 27d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-23 Deutsche Bank AG Invests $12.16 Million in Arrowhead Pharmaceuticals, Inc. $ARWR Deutsche Bank AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 149,240 shares of the biotechnology company''s stock, valued at approximately $12,165,000. Deutsche Bank AG owned 0.11% of Arrowhead Pharmaceuticals at the end
- 2026-08-17 People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) are the among first in the European Union to have a new treatment option to reduce dangerously high levels of triglycerides (TGs, a type of fat) in their bloodstream. Following its marketing authorization by the European Commission in June 2026, REDEMPLO® (plozasiran) is now listed in the.
- 2026-08-04 Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript
- 2026-08-04 Arrowhead Pharmaceuticals Q3 Earnings Call Highlights Arrowhead Pharmaceuticals NASDAQ: ARWR reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlighting continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome (FCS).
- 2026-08-04 Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from.
- 2026-08-04 Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). The company intends to utilize the PRV for its upcoming Supplemental New Drug Application (sNDA) submission for plozasiran, anticipated before the end of 2026, to seek approval to expand the approved indication to include patients.
- 2026-08-04 California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR California State Teachers Retirement System raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 21.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,313 shares of the biotechnology company''s stock after acquiring an additional 25,941 shares during
- 2026-08-03 Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company''s Board of Directors approved “inducement” grants to 95 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 112,794 restricted stock units. The grants are outside the Company''s stockholder-approved equity incentive plans and vest.
- 2026-07-27 Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia [url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of z
- 2026-07-27 Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company''s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated low density lipoprotein-cholesterol (LDL-C) and early onset cardiovascular disease. Arrowhe.